US Executive Compensation Proxy SEC Filings — April 29, 2026

29-04-2026

Massimo Group's DEF 14A proxy statement details its board of directors and executive officers, including Executive Chairman David Shan (60), CEO Quenton Petersen (36), and CFO Crystal Mingqiu Xu (46), alongside three independent directors: Paolo Pietrogrande, Ting Zhu, and Mark Sheffield. The four-member board held four meetings in fiscal year 2025 with all directors attending at least 75% of meetings and committees; it oversees Audit, Compensation, and Nominating Committees with standard charters. As a controlled company with David Shan holding over 50% voting power, it qualifies for certain Nasdaq exemptions but does not currently plan to use them.

• ·No family relationships among directors or executive officers.
• ·No involvement in certain legal proceedings by directors or executives in the past ten years.
• ·Board oversees risk management with management handling day-to-day processes.
• ·Code of Business Conduct adopted and available on company website.

29-04-2026

United Therapeutics Corporation's 2026 Proxy Statement details the virtual Annual Meeting of Shareholders on June 26, 2026, proposing the election of twelve directors, an advisory vote on executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of Ernst & Young LLP as independent auditors for 2026. The company highlights robust 2025 financial performance, including 11% revenue growth year-over-year, $1.3B net income, $4.7B in cash and equivalents, $1.0B returned to shareholders via accelerated share repurchase, and 38% total shareholder return. Pipeline progress features positive unblinding results from the ADVANCE OUTCOMES study for ralinepag in PAH and TETON studies for nebulized Tyvaso in pulmonary fibrosis.

• ·Record Date for voting eligibility: April 28, 2026
• ·Annual Meeting: Friday, June 26, 2026, at 10:30 a.m. Eastern Time, virtual via shareholdermeeting.com/UTHR2026
• ·Proxy materials first distributed on or about April 29, 2026

29-04-2026

908 Devices Inc. (MASS) has filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 11, 2026 at 10:00 a.m. ET. Key proposals include electing three Class III directors (Keith L. Crandell, Christopher Brown, Ph.D., and E. Kevin Hrusovsky) to serve until the 2029 annual meeting, ratifying PricewaterhouseCoopers LLP as independent auditors for FY 2026, an advisory vote to approve named executive officer compensation, and an advisory vote on the frequency of future say-on-pay votes. The record date is April 16, 2026, with 37,446,534 shares of common stock outstanding.

• ·Annual Meeting held virtually at https://meetnow.global/MC2YHGH
• ·Record date: April 16, 2026
• ·Proxy materials and 2025 Annual Report (filed March 9, 2026) available at www.envisionreports.com/MASS and SEC website
• ·Voting deadline for proxies: 1:00 a.m. ET on June 11, 2026

29-04-2026

C4 Therapeutics reported key 2025 achievements including Phase 1 data for cemsidomide in multiple myeloma, collaborations with Pfizer and Betta Pharma, milestone payments from Merck KGaA and Biogen, a new discovery strategy, and $125M raised via underwritten offering extending cash runway. However, the company decided not to advance CFT1946 beyond Phase 1 due to emerging data. This DEF 14A proxy statement solicits votes for the June 24, 2026 annual meeting on electing three Class III directors, advisory approval of executive compensation, ratification of KPMG LLP as auditors, and amending the 2020 Plan's evergreen provision.

• ·Annual Meeting scheduled for June 24, 2026; Record Date April 27, 2026
• ·Proposals include election of three Class III directors to serve until 2029 annual meeting
• ·No undesignated preferred stock outstanding as of April 27, 2026

29-04-2026

Legence Corp.'s DEF 14A proxy statement details 2025 executive compensation, including IPO-related equity awards under the 2025 Omnibus Incentive Plan with target values ranging from $400,000 (J. Schwartz) to $3,500,000 (J. Sprau), comprising RSUs and stock options vesting over three years. It describes historical Series A Profits Interests under Legence Parent and Parent II plans, with 60% time-vesting, 20% performance-vesting at 1.5x MOIC threshold, and 20% exit-vesting, granted to named executives in various amounts during 2021-2025. Employment agreements include severance benefits and restrictive covenants, with no reported declines in compensation metrics.

• ·Series A Profits Interests include Time Interests (60%, vest quarterly over 5 years), Performance Interests (20%, vest at 1.5x MOIC), and Exit Interests (20%, vest on Change of Control Exit).
• ·RSUs and stock options vest in equal installments over three anniversaries, with acceleration on Change in Control or qualifying termination.
• ·401(k) plan offers up to 4% match on eligible contributions, fully vested; Mr. Hansen receives union pension benefits.
• ·Restrictive covenants include indefinite confidentiality/non-disparagement, 2-year non-solicit, and non-compete terms.

29-04-2026

Shoulder Innovations, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 26, 2026, at 3:00 p.m. ET, with a record date of April 27, 2026. Shareholders are asked to vote on Proposal No. 1: election of two Class I directors for three-year terms; and Proposal No. 2: ratification of Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026. The Board unanimously recommends voting FOR both proposals, with 20,727,949 shares of common stock outstanding as of the record date.

• ·Annual Meeting accessible at www.virtualshareholdermeeting.com/SI2026 using 16-digit control number.
• ·Voting methods: internet at www.ProxyVote.com, phone at 1-800-690-6903, or mail to Broadridge.
• ·Proxy materials available at www.shoulderinnovations.com and www.ProxyVote.com.

29-04-2026

Citizens Community Bancorp, Inc. (CZWI) filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders on June 16, 2026, at 4:00 p.m. local time in Eau Claire, Wisconsin, with a record date of April 10, 2026, and 9,628,612 shares of Common Stock outstanding. Shareholders will vote on electing directors Michael Conner, Francis Felber, and Nicholas Amundsen for three-year terms; approving the 2026 Omnibus Incentive Plan; a non-binding advisory vote on executive compensation; and ratifying Crowe LLP as independent auditors for FY 2026. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Annual Meeting location: Holiday Inn Eau Claire South, 4751 Owen Ayres Ct, Eau Claire, Wisconsin 54701.
• ·Quorum requires stockholders holding a majority of Common Stock entitled to vote, present in person or by proxy.
• ·Directors elected by plurality vote; other proposals require majority of votes cast.
• ·Proxy solicitation primarily by mail, with assistance from Regan & Associates.

29-04-2026

LivaNova PLC's DEF 14A Proxy Statement for the 2026 virtual AGM details 10 proposals, including director elections, U.S. and UK say-on-pay votes, ratification of PwC-U.S. and PwC-UK as auditors, share allotment authority, disapplication of pre-emption rights (special resolution), share repurchase approvals, adoption of the UK Annual Report and Accounts, and auditor remuneration authorization. The Board highlights strong governance with 10 of 11 independent directors, annual elections under majority voting, separate CEO/Chair roles, and diversity (4 female directors); average tenure is 5 years 4 months. No performance declines noted, but all resolutions emphasize routine and non-routine voting with broker non-votes applicable to non-routine matters.

• ·AGM record date: April 13, 2026
• ·Mr. Zurbay appointed as independent director: September 2025
• ·Virtual AGM access: www.meetnow.global/MM4W4G7 (requires control number)
• ·One special resolution (Proposal 5: disapply pre-emption rights, requires 75% approval)
• ·Director stock ownership guideline: 5x annual cash retainer for non-executives

29-04-2026

Titan Machinery Inc. (TITN) filed its DEF 14A Proxy Statement on April 29, 2026, for the virtual 2026 Annual Meeting of Stockholders on June 8, 2026, at 9:00 a.m. CT. Stockholders of record as of April 10, 2026, will vote on electing three Class I directors for three-year terms, an advisory vote on named executive officer compensation, and ratification of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending January 31, 2027. No financial performance metrics or changes are detailed in the provided filing content.

• ·Virtual Annual Meeting accessible at www.virtualshareholdermeeting.com/TITN2026; login recommended 15 minutes early.
• ·Proxy materials available via Notice of Internet Availability sent on or about April 29, 2026; full documents on company website.
• ·Quorum requires majority of outstanding shares entitled to vote as of record date.
• ·XBRL tags reference equity compensation adjustments for Principal Executive Officer (PEO) and Non-PEO Named Executive Officers (NEOs) across fiscal years ending January 31, 2022 through 2027, but no specific values provided.

29-04-2026

Willow Tree Capital Corporation has filed a definitive proxy statement (DEF 14A) for its 2026 virtual Annual Meeting of Stockholders on June 25, 2026, at 1:00 p.m. ET, solely to elect two directors for three-year terms. The record date is April 10, 2026, with 26,235,272 shares of common stock outstanding, and stockholders are urged to vote by proxy, phone, mail, internet, or virtually. The Board recommends voting 'FOR' both nominees; no other matters are anticipated.

• ·Meeting website: www.virtualshareholdermeeting.com/WTCC2026
• ·Company address: 450 Park Avenue, 29th Floor, New York, NY; Phone: (212) 218-1090
• ·Proxy materials and Annual Report for fiscal year ended December 31, 2025 available at www.proxyvote.com
• ·Proposal 1 is non-routine; broker non-votes possible but abstentions count toward quorum

29-04-2026

AbCellera Biologics Inc. filed its DEF 14A proxy statement on April 29, 2026, for the virtual 2026 Annual Meeting of Shareholders on June 11, 2026, at 9:00 a.m. Pacific Time. Key proposals include electing two Class III directors to serve until the 2029 Annual Meeting, ratifying Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026, and a non-binding advisory vote on named executive officer compensation. As of the record date April 15, 2026, 305,264,947 common shares were outstanding, all entitled to one vote per share.

• ·Annual Meeting held virtually at www.proxydocs.com/ABCL; control number required to attend and vote
• ·Notice of Internet Availability of Proxy Materials mailed on or about April 29, 2026
• ·Proxy materials and 2025 Annual Report available at www.proxydocs.com/ABCL and www.abcellera.com

29-04-2026

Terex Corporation's DEF 14A Proxy Statement for the June 25, 2026 virtual Annual Meeting highlights strong 2025 financial performance with net sales of $5.4 billion, adjusted operating margin of 10.4%, and adjusted EPS of $4.93, alongside $98 million returned to shareholders via repurchases and dividends. The document notes successful integration of the Environmental Solutions Group acquired in October 2024 and the completion of a transformational merger with REV Group, Inc. in February 2026, positioning Terex in resilient end markets. No declines or flat metrics are reported in the provided financial highlights.

• ·Annual Meeting Date and Time: June 25, 2026, at 10:00 a.m. Eastern Time, virtual at www.virtualshareholdermeeting.com/terex2026
• ·Record Date: April 27, 2026
• ·Agenda: (1) Elect 12 directors; (2) Advisory vote on named executive officer compensation; (3) Approve Terex Corporation 2026 Omnibus Incentive Plan; (4) Ratify KPMG LLP as independent auditor for 2026
• ·All directors independent except CEO; Non-Executive Chairman structure in place

29-04-2026

Forte Biosciences, Inc. (FBRX) filed a DEF 14A proxy statement on April 29, 2026, for its annual meeting of stockholders, proposing the election of three Class III directors: Steven Kornfeld, Scott Brun, M.D., and Paul A. Wagner, Ph.D. (Chairman, President, and CEO), to serve until 2029. The Board comprises eight directors, six of whom are independent under Nasdaq standards, with no reported changes in composition or performance metrics. Stockholder proposal deadlines for the 2027 annual meeting include December 30, 2026, for inclusion in the proxy statement, and advance notices between January 29 and February 28, 2027.

• ·Ages of directors as of April 17, 2026: Steven Kornfeld (58), Scott Brun (58), Paul A. Wagner (55), Barbara K. Finck (79), Stephen K. Doberstein (67), Richard Vincent (63), Shiv Kapoor (51), David Gryska (70).
• ·Company address: 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247; Tel: (310) 618-6994; Email: investors@fortebiorx.com.
• ·Advance notice for 2027 stockholder proposals (not for proxy inclusion): not earlier than January 29, 2027 at 5:00 p.m. ET and not later than February 28, 2027 at 5:00 p.m. ET.

29-04-2026

Matador Resources Company's 2026 Proxy Statement highlights record 2025 operational performance with 20% YoY oil production growth to 43.7 million Bbl, 23% natural gas production increase to 191.3 Bcf, and 21% average daily BOE growth to 207,070, alongside strong financials including $2.43B net cash from operations, $437.0M adjusted free cash flow, $1.8B liquidity, and 1.1x leverage ratio. The company increased its annual dividend to $1.50 per share, repurchased $55.8M in shares (1.35M shares at $41.31 avg), and maintained capital expenditures at $1.53B within guidance. No declines or flat metrics were reported; shareholders will vote on director elections, advisory NEO compensation approval, and KPMG ratification at the June 11, 2026 Annual Meeting.

• ·Annual Meeting scheduled for June 11, 2026 at 9:30 a.m. CDT at Hilton Dallas Lincoln Centre, Dallas, Texas.
• ·Record date for voting: close of business on April 13, 2026.
• ·Proposals: (1) Election of three director nominees; (2) Advisory vote on NEO compensation; (3) Ratification of KPMG LLP for year ending December 31, 2026.
• ·D/C/E capital expenditures within guided range of $1.47B to $1.55B.

29-04-2026

SANUWAVE Health, Inc. has filed a definitive proxy statement for its virtual annual stockholder meeting on June 11, 2026, at 10:00 a.m. Central Time, seeking approval for the election of five directors (Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, and James Tyler), ratification of Baker Tilly US, LLP as independent auditor for the fiscal year ending December 31, 2026, and an advisory vote to approve named executive officer compensation. The record date is April 20, 2026, with 8,598,209 shares of common stock outstanding entitled to vote. The Board unanimously recommends voting 'FOR' all three proposals.

• ·Quorum requires holders of at least one-half of outstanding shares as of record date.
• ·Proposal 1 (Director Election) requires plurality vote; Proposals 2 and 3 require more 'For' than 'Against'.
• ·Broker discretionary voting allowed only for Proposal 2 (auditor ratification); non-votes and abstentions have no effect on any proposal.
• ·Proxy materials and 2025 Annual Report available at https://www.virtualshareholdermeeting.com/SNWV2026.

29-04-2026

Xometry's 2026 Proxy Statement highlights record 2025 performance, including $687 million in revenue (26% YoY growth, accelerating 8 points from 2024), core marketplace growth of 30% YoY, Adjusted EBITDA profitability of $18.5 million, and marketplace gross margin expansion of 120 basis points to 34.7% with 34% gross profit growth. Enterprise revenue grew over 40% from larger customers, ending the year with four accounts each generating at least $10 million in spend and a global network of approximately 5,000 active suppliers. It also announces a leadership transition effective July 1, 2026, with President Sanjeev Singh Sahni succeeding the current CEO as CEO while the outgoing CEO becomes Executive Chair.

• ·2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026 at 11:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/XMTR2026
• ·Leadership transition announced in February 2026, effective July 1, 2026

29-04-2026

Liberty Global Ltd.'s DEF 14A proxy statement, filed April 29, 2026, nominates Miranda Curtis CMG, J David Wargo, and Anthony G. Werner for re-election as Class I directors at the 2026 AGM, to serve until the 2029 AGM. The document details the responsibilities of key board committees, including Audit (overseeing auditors and internal controls), Compensation (setting executive pay and retaining The Croner Company in 2025 for peer group updates), Nominating and Corporate Governance (handling director nominations), People Planet Progress (ESG oversight), and Succession Planning (CEO succession). No financial performance metrics, growth, declines, or period comparisons are provided.

• ·Shareholder director nominations must be submitted in writing to Nominating and Corporate Governance Committee, Liberty Global Ltd., 1550 Wewatta Street, Suite 1000, Denver, Colorado 80202, Attn: General Counsel, including specific required information and candidate consent.
• ·Nominating and Corporate Governance Committee considers diversity broadly, including perspectives, opinions, professional backgrounds, and experiences, but has no formal diversity policy.
• ·Compensation Committee reviews compensation risks annually and shareholder say-on-pay votes.

29-04-2026

MapLight Therapeutics' DEF 14A proxy statement proposes the election of three Class I directors at the 2026 Annual Meeting: incumbent George Pavlov and nominees Martin Babler and Troy Cox, to replace Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who notified the Board on April 23, 2026, that they will not stand for reelection. The Board currently consists of seven members divided into three classes, with Class II terms expiring in 2027 and Class III in 2028. Deadlines for 2027 stockholder proposals are January 1, 2027, with nomination notices required between February 23, 2027, and March 25, 2027.

• ·Vacancies on the Board may be filled only by majority vote of remaining directors.
• ·Directors elected by plurality vote of shares present or by proxy.
• ·Nominees identified by third-party search firm and recommended by Nominating and Corporate Governance Committee.
• ·Stockholder notices must comply with bylaws (Exhibit 3.2 to Form 8-K filed October 29, 2025).
• ·During 2025, directors elected by written consent without annual meeting.

29-04-2026

MiMedx Group, Inc. (MDXG) has filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders, to be held virtually on June 10, 2026, at 9:00 a.m. ET, seeking to elect seven directors, approve executive compensation on an advisory basis, and ratify Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026. The record date is April 13, 2026 (5:00 p.m. ET), with 148,945,731 shares of common stock outstanding entitled to vote. The Board unanimously recommends voting FOR all proposals; no financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/MDXG2026; pre-registration required by 5:00 p.m. ET on June 9, 2026 via www.proxyvote.com.
• ·Proxy materials (Notice, Proxy Statement, 2025 Form 10-K) available at www.proxyvote.com as of April 29, 2026.
• ·Named proxies: William F. Hulse IV and Kendall Lioon.

29-04-2026

Ardelyx, Inc. (ARDX) filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 16, 2026, seeking approval for electing three Class III directors (Robert Bazemore, Muna Bhanji, R.Ph., and Richard Rodgers), an advisory 'Say-on-Pay' vote on NEO compensation, a vote on Say-on-Pay frequency (board recommends every one year), ratification of Ernst & Young LLP as auditors for FY 2026, and an amendment to increase shares under the Restated 2014 Equity Incentive Plan by 9,000,000 shares. The board emphasizes strong governance, including 100% independent committees, 95% average director attendance in 2025, pay-for-performance practices, and projected equity overhang of 26.3% in line with prior years. No performance declines or flat metrics are noted in the filing.

• ·Record date: April 22, 2026
• ·Voting deadline: 11:59 p.m. ET on June 15, 2026 (Internet/telephone/mail)
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/ARDX2026
• ·All directors except CEO are independent; independent board chairperson
• ·No evergreen provisions in equity plan; stockholder vote required for share increases
• ·Minimum stock ownership policy for executives and directors adopted in late 2025

29-04-2026

Penumbra, Inc.'s DEF 14A proxy statement for the June 18, 2026 annual meeting seeks stockholder approval for electing three Class II directors, ratifying PricewaterhouseCoopers LLP as auditors for FY 2026, and an advisory vote on named executive officer compensation. The filing highlights a January 14, 2026 merger agreement with Boston Scientific Corporation valuing the enterprise at $14.5 billion ($374 per share, 73% cash/27% stock consideration), with a separate special meeting for merger approval and expected close by end of 2026. No period-over-period financial comparisons or declines are provided.

• ·Annual Meeting location: building 1310, One Penumbra Place, Alameda, CA 94502 at 11:00 a.m. PDT on June 18, 2026
• ·Record Date: April 22, 2026
• ·Proxy voting deadline: 11:59 p.m. EDT on June 17, 2026 via phone or internet
• ·Merger stock exchange ratio: 3.8721 shares of Boston Scientific common stock per Penumbra share
• ·Merger proxy statement/prospectus filed with SEC on April 1, 2026

29-04-2026

OmniAb, Inc. will hold its 2026 Annual Meeting of Shareholders on June 17, 2026, at 8:00 a.m. PT in Emeryville, CA, to elect Matthew W. Foehr and Jennifer Cochran, Ph.D. as Class I Directors for terms expiring in 2029 and to ratify Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The proxy highlights strong corporate governance practices, including a 7-member board with all directors independent except the CEO, 100% committee independence, separate Board Chair and CEO roles, and stock ownership guidelines. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Record Date: April 23, 2026
• ·Meeting location: 5980 Horton Street, Suite 600, Emeryville, CA 94608
• ·Notice of Internet Availability mailing expected on or about May 5, 2026
• ·Board committees: Audit, Nominating and Corporate Governance (NCG), Human Capital Management and Compensation (HCMC), Science and Technology

29-04-2026

CorMedix Inc. reported transformative FY2025 financial results with total revenue of $311.7 million, including $258.8 million from DefenCath net sales and $52.9 million from the partial-year Melinta portfolio, achieving net income of $163.0 million ($2.04 per diluted share) compared to a $17.9 million net loss in FY2024. The company closed its acquisition of Melinta Therapeutics LLC in August 2025, adding a diversified portfolio of specialty injectable pharmaceuticals such as MINOCIN, REZZAYO, VABOMERE, ORABACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. This proxy statement for the June 23, 2026 virtual annual meeting seeks stockholder approval for director elections, say-on-pay, auditor ratification, and several governance-focused charter amendments, while noting 2026 as a transitional year due to DefenCath reimbursement changes.

• ·Annual Meeting: June 23, 2026 at 9:00 a.m. ET, virtual-only at www.virtualshareholdermeeting.com/CRMD2026
• ·Record date: April 24, 2026
• ·Proposals include ratification of prior amendments to Series E Preferred Stock and Series C-3 Preferred Stock certificates of designation (Proposal 4), technical charter amendments (Proposal 5), class voting for preferred stock changes (Proposal 6), exclusive forum provisions (Proposal 7), and officer liability limitations (Proposal 8)

29-04-2026

Verano Holdings Corp. (VRNO) filed a DEF 14A Proxy Statement dated April 29, 2026, for its 2026 Annual Meeting of Stockholders on June 18, 2026, via live webcast, soliciting votes on electing five directors, advisory approval of named executive officer compensation (Say-on-Pay), ratification of Macias Gini & O’Connell LLP (MGO) as independent auditor for the year ending December 31, 2026, and reapproval of the Verano Holdings Corp. Stock and Incentive Plan with unallocated entitlements extended to June 18, 2029. The Board recommends voting 'FOR' all proposals. No financial performance metrics or period-over-period changes are detailed in the filing excerpt.

• ·Meeting begins at 9:30 a.m. Central time at www.virtualshareholdermeeting.com/VRNO2026
• ·Proxy materials and Annual Report on Form 10-K for fiscal year ended December 31, 2025, available on https://investors.verano.com, SEC website, and SEDAR+
• ·Notice to stockholders mailed on or about May 8, 2026
• ·Proposal 1 uses plurality voting subject to Majority Voting Policy; Proposals 2, 3, and 4 require majority of votes cast FOR exceeding AGAINST
• ·Proposal 3 is routine (broker discretionary voting); others are non-routine

29-04-2026

29-04-2026

29-04-2026

WisdomTree, Inc.'s DEF 14A proxy statement discloses Compensation Actually Paid (CAP) for PEO Jonathan Steinberg, which grew from $4.3M in 2021 to a peak of $15.3M in 2024 (+54% YoY from 2023), but declined 35% YoY to $9.9M in 2025 amid negative equity vesting fair value changes. Average CAP for Other NEOs followed a similar pattern, rising from $1.3M in 2021 to $4.4M in 2024 before dropping 23% to $3.4M in 2025. Summary Compensation Table totals remained relatively flat, with PEO around $6.7M and average Other NEOs around $2.5M across recent years.

• ·Mr. Edmiston appointed CFO effective June 1, 2021.
• ·Proxy statement filed April 29, 2026, for period ending June 17, 2026 (likely annual meeting date).
• ·Equity award adjustments include negative fair value changes for vested prior-year awards in 2025: -$375,717 for PEO and -$75,861 average for Other NEOs.

29-04-2026

Fidelity National Financial, Inc. (FNF) issued its DEF 14A proxy statement for the virtual Annual Meeting on June 10, 2026, seeking shareholder approval for electing four Class III directors, amending articles for annual director elections, advisory vote on 2025 executive compensation, and ratifying Ernst & Young LLP as auditors. The company reported strong 2025 performance with $14.3 billion in total revenue (excluding $160 million noncash gains) and $679 million in net earnings, while returning $2.5 billion in dividends and $1.3 billion in share repurchases to shareholders from 2021-2025. FNF maintains 70% ownership of F&G after distributing additional 16,280,204 F&G shares on December 31, 2025.

• ·Annual Meeting record date: April 13, 2026.
• ·Proxy materials first mailed on or about April 29, 2026.
• ·Board recommends 'FOR' all proposals: director elections (Proposal 1), amend articles for annual director elections (Proposal 2), say-on-pay (Proposal 3), and auditor ratification (Proposal 4).

29-04-2026

Axogen, Inc. filed its DEF 14A definitive proxy statement on April 29, 2026, for the virtual 2026 Annual Meeting of Shareholders on June 23, 2026, at 8:30 a.m. ET. Shareholders will vote to elect eight board members, ratify Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026, and approve named executive officer compensation on a non-binding advisory basis. The record date is April 24, 2026, with proxy materials accessible online.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/AXGN2026
• ·Voting methods: telephone (1-800-690-6903), internet (www.proxyvote.com), or mail; deadline 11:59 p.m. ET on June 22, 2026
• ·Notice of Internet Availability mailed on or about April 29, 2026
• ·Company address: 13631 Progress Blvd., Suite 400, Alachua, FL 32615
• ·Fiscal year end: December 31; references 2025 Annual Report (Form 10-K for year ended December 31, 2025)

29-04-2026

Candel Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders, to be held virtually on June 23, 2026 at 10:00 a.m. ET, with record date April 24, 2026, and 73,270,239 shares of common stock outstanding. Shareholders will vote on electing four Class II directors to serve until the 2029 annual meeting and ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The company, an emerging growth company under the JOBS Act, uses the Notice and Access model for proxy materials to reduce costs and environmental impact.

• ·No shares of preferred stock outstanding as of April 24, 2026
• ·Virtual meeting access at www.virtualshareholdermeeting.com/CADL2026 requiring 16-digit control number
• ·Proxy materials and 2025 Annual Report available at www.ProxyVote.com, SEC website, and ir.candeltx.com
• ·Emerging growth company status until earliest of specified events post-IPO in July 2021

29-04-2026

IDEAYA Biosciences, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 16, 2026, at 1:30 p.m. Pacific Time, with a record date of April 20, 2026. Shareholders are voting on three proposals: election of three Class I directors for terms expiring in 2029, ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, and a non-binding advisory vote to approve named executive officer compensation. As of the record date, 87,860,920 shares of common stock ($0.0001 par value) were outstanding.

• ·Annual Meeting held entirely online; register at www.proxydocs.com/IDYA
• ·Notice of Internet Availability of Proxy Material mailed on or about April 29, 2026
• ·Proxy solicitation costs borne by the Company
• ·Voting requires majority of voting power present in person or by proxy

29-04-2026

Cypherpunk Technologies Inc. has issued a proxy statement for its virtual Annual Meeting on June 18, 2026, at 11:00 a.m. ET, seeking stockholder approval for electing two Class III directors (Nissim Mashiach and Will McEvoy to serve until 2029), an advisory vote on executive compensation, and ratification of EisnerAmper LLP as independent auditors for the year ending December 31, 2026. The record date is April 29, 2026, with 97,678,728 shares of Common Stock outstanding as of April 20, 2026. No financial performance metrics or period-over-period comparisons are discussed.

• ·Notice of Internet Availability to be mailed on or about May 9, 2026
• ·Proxy voting deadline: 11:59 p.m. ET on June 17, 2026
• ·Quorum requires majority in voting power of capital stock entitled to vote
• ·Proposal 1 (Director Election): Plurality vote, non-discretionary
• ·Proposal 2 (Say-on-Pay): Majority of votes cast, non-discretionary
• ·Proposal 3 (Auditor Ratification): Majority of votes cast, discretionary

29-04-2026

Shoe Carnival, Inc. (SCVL) has issued its DEF 14A proxy statement for the 2026 annual shareholder meeting on June 10, 2026, proposing the election of directors Diane E. Randolph and J. Wayne Weaver to serve until 2029, an advisory vote to approve named executive officer compensation, ratification of Deloitte & Touche LLP as independent auditors for Fiscal 2026, and an amendment to the articles of incorporation to change the company name to Shoe Station Group, Inc. The Board recommends voting FOR all proposals, with materials furnished primarily via the Internet and a record date of April 13, 2026. No financial performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Annual meeting location: 1800 Innovation Point, Fort Mill, South Carolina, at 11:00 a.m. EDT.
• ·Record date for voting eligibility: April 13, 2026.
• ·Proxy materials mailed on or about April 29, 2026, primarily via Internet availability notice.

29-04-2026

Kymera Therapeutics, Inc. (KYMR) filed its DEF 14A Proxy Statement on April 29, 2026, for the 2026 Annual Meeting of Shareholders to be held virtually on June 24, 2026, at 8:30 a.m. ET. As of the record date, April 27, 2026, 82,257,588 shares of common stock (par value $0.0001 per share) were outstanding, each entitled to one vote. Proxy materials are available online, with voting options including internet, phone, mail, QR code, or during the virtual meeting, and deadlines by 11:59 p.m. ET on June 23, 2026.

• ·Annual Meeting virtual webcast at www.virtualshareholdermeeting.com/KYMR2026; online check-in begins at 8:15 a.m. ET.
• ·No shares of undesignated preferred stock outstanding as of April 27, 2026.
• ·2025 Annual Report on Form 10-K for fiscal year ended December 31, 2025, available with proxy materials.
• ·Company address: 500 North Beacon Street, Fourth Floor, Watertown, Massachusetts 02472.

29-04-2026

Black Diamond Therapeutics, Inc. issued its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders, scheduled virtually on June 26, 2026, at 9:00 a.m. ET, with a record date of April 28, 2026, on which 57,301,774 shares of common stock were outstanding. Proxy materials, including the 2025 Form 10-K, are available online starting April 29, 2026, with voting via internet/phone by 11:59 p.m. ET on June 25, 2026, or mail prior to June 26, 2026.

• ·Meeting accessible via live webcast at www.virtualshareholdermeeting.com/BDTX2026; stockholders need 16-digit control number.
• ·Proposals include No. 1 (election of directors, plurality vote), No. 2 (ratify appointment, majority of votes cast), No. 3 and No. 4 (non-discretionary).
• ·Quorum requires majority of outstanding shares present virtually or by proxy.

29-04-2026

Adicet Bio, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders, to be held virtually on June 17, 2026 at 5:00 p.m. ET, with stockholders of record as of April 21, 2026 entitled to vote. The meeting includes proposals to elect three Class II directors to serve until the 2029 annual meeting, approve on a non-binding advisory basis the compensation of named executive officers, and ratify KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Proxy materials and the 2025 Annual Report are available online via Notice and Access, with notices mailed on or about April 29, 2026.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/ACET2026 (requires 16-digit control number)
• ·Principal executive office: 131 Dartmouth Street, 3rd Floor, Boston, Massachusetts 02116

29-04-2026

PDF Solutions Inc (PDFS) filed its DEF 14A Proxy Statement on April 29, 2026, for the 2026 Annual Meeting, disclosing XBRL-tagged executive compensation data structures for the Principal Executive Officer (PEO) and Non-PEO Named Executive Officers (NEOs) covering equity award fair value changes, vesting, and adjustments from 2021 to 2025. The filing details corporate governance practices, including a Code of Ethics supplemented by the RBA Code of Conduct, compliance with Nasdaq and Sarbanes-Oxley requirements, and ESG oversight by the Board, NCG, CHCM, and Audit Committees. The Audit Committee Report approves the inclusion of audited 2025 financial statements in the Form 10-K, with no performance declines or flat metrics noted.

• ·Audit Committee oversees cybersecurity risks and environmental/sustainability risks.
• ·ESG Steering Committee chaired by General Counsel assists NCG Committee.
• ·Proxy Statement references governance documents available at https://www.pdf.com/company/governance/.

29-04-2026

Niagen Bioscience, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders on June 24, 2026, at 3:00 p.m. PT, proposing the election of eight director nominees, ratification of Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and an advisory vote to approve named executive officer compensation. The record date is April 27, 2026, with 79,644,327 shares of common stock outstanding entitled to vote. Proxy materials were made available online beginning April 29, 2026.

• ·Annual Meeting location: 10900 Wilshire Boulevard, Suite 600, Los Angeles, California 90024.
• ·Proxy voting deadline: 11:59 p.m. Eastern Time on June 23, 2026 (phone: 1-800-652-VOTE; internet: www.investorvote.com/NAGE).
• ·Notice of Internet Availability mailed on or about April 30, 2026.

29-04-2026

Rocket Companies, Inc. (RKT) issued its DEF 14A Proxy Statement for the June 10, 2026 annual meeting, highlighting 2025 achievements including $5B annualized recurring cash flow from servicing, 62 million monthly active users across Rocket and Redfin, 460,000 homebuyers served via origination, and a 9.5 million client servicing portfolio. The company announced a three-year strategic partnership with Compass in early 2026 to enhance inventory, lead flow, and mortgage integration. Proprietary AI drives efficiency, automating 800,000 chats, 1.8 million texts, 2 million calls, and 5 million documents monthly, capturing $1B in incremental volume per month.

• ·Record date: April 15, 2026
• ·Annual meeting: June 10, 2026 (virtual only)
• ·Proposals include election of Class III directors, ratification of auditors for 2026, and approval of amendment to Team Member Stock Purchase Plan

29-04-2026

SenesTech, Inc. will hold its 2026 Annual Meeting of Stockholders on June 9, 2026, at 12:00 p.m. MST to elect Jake S. Leach and Joshua M. Moss as Class I directors for three-year terms, approve an advisory 'say-on-pay' vote on 2025 executive compensation, amend the 2018 Equity Incentive Plan by adding 1,700,000 shares, and ratify M&K CPAS, PLLC as auditors for the fiscal year ending December 31, 2026. The record date is April 20, 2026, with 5,265,744 shares of common stock outstanding. The company retained Alliance Advisors, LLC for proxy solicitation services at a fixed fee of $11,500 plus expenses.

• ·Quorum requires holders of one-third (1/3) of outstanding shares present in person or by proxy.
• ·Annual Meeting location: 13430 North Dysart Road, Suite 105, Surprise, Arizona 85379.
• ·Voting deadline: 11:59 p.m. Eastern Daylight Time on June 8, 2026 for internet/telephone.
• ·Proposals 1, 2, and 3 are non-routine; Proposal 4 (auditor ratification) is routine.

29-04-2026

Usio, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting on June 10, 2026, at 10:00 a.m. CDT in San Antonio, TX, with a record date of April 13, 2026. Shareholders will vote on electing Class III directors Ernesto R. Beyer and Bradley Rollins (until 2029), advisory approval of 2025 Named Executive Officer compensation, and ratification of Withum Smith+Brown, PC as independent auditors for 2026; the Board recommends FOR all proposals. As of the record date, 27,621,564 shares of common stock were outstanding, excluding 3,997,765 treasury shares.

• ·Notice of Internet Availability mailing commences on or about April 29, 2026
• ·Online participation registration deadline: 12:00 p.m. CDT on June 9, 2026, via ir@usio.com or (210) 249-4050
• ·Stockholder list available for inspection 10 days prior to meeting at company offices
• ·Proxy materials available at www.proxyvote.com, www.usio.com/proxy, www.usio.com/10k, or via IR email

29-04-2026

Monte Rosa Therapeutics, Inc. (GLUE) filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders, to be held virtually on June 11, 2026 at 8:30 a.m. ET via www.proxydocs.com/GLUE. The meeting agenda includes electing three Class II director nominees to serve until the 2029 annual meeting and ratifying Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is April 16, 2026, with 84,382,573 shares of common stock outstanding; proxy materials are available via notice and access model mailed on or about April 29, 2026.

• ·Annual Meeting registration deadline: June 9, 2026 at 5:00 p.m. Eastern Time
• ·Initial public offering occurred in June 2021
• ·Emerging growth company status ends at the earliest of: last day of FY following fifth anniversary of IPO, $1.235B annual gross revenue, $1B nonconvertible debt in prior three years, or large accelerated filer status
• ·Proxy materials and 2025 Annual Report available at www.proxydocs.com/GLUE and SEC website

29-04-2026

ARS Pharmaceuticals, Inc. (SPRY) filed its 2026 DEF 14A Proxy Statement for the Annual Meeting on June 24, 2026, seeking stockholder approval for electing three Class III directors, ratifying Ernst & Young LLP as independent auditors for FY 2026, advisory approval of executive compensation, and a one-year frequency for future say-on-pay votes. The accompanying letter highlights the successful commercial launch of neffy® epinephrine nasal spray, with over 22,500 healthcare providers prescribing it to date and achieving over 90% commercial coverage, bolstered by $245 million in cash, cash equivalents, and short-term investments at year-end 2025 to fund operations through breakeven. The company is advancing a Phase 2b trial for neffy in chronic spontaneous urticaria (CSU), targeting ~2 million U.S. patients, with interim data expected in H2 2026.

• ·Annual Meeting record date: April 27, 2026
• ·Virtual meeting format only via www.proxydocs.com/SPRY; advance registration required by June 23, 2026 at 5:00 p.m. ET
• ·neffy approvals secured by partners in Europe, China, Japan, Australia, and Canada

29-04-2026

Damora Therapeutics, Inc. (formerly Galecto, Inc., ticker GLTO changed to DMRA) issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 17, 2026 at 9:00 a.m. ET, with a record date of April 22, 2026. The meeting agenda includes electing Michael Landsittel and Cameron Turtle, D.Phil. as Class III directors for a three-year term, an advisory vote to approve named executive officer compensation, an advisory vote on the frequency of future say-on-pay votes, and ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The proxy follows the November 10, 2025 acquisition of Damora Therapeutics and the March 10, 2026 name change.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/DMRA2026 (requires 16-digit control number).
• ·Proxy materials available at www.proxyvote.com.
• ·Acquisition completed November 10, 2025 via Agreement and Plan of Merger.
• ·Name change from Galecto, Inc. to Damora Therapeutics, Inc. effective March 10, 2026; Nasdaq ticker changed from GLTO to DMRA.

29-04-2026

Global Self Storage, Inc. (SELF) has issued a proxy statement for its Annual Meeting of Stockholders on June 16, 2026, held virtually, seeking approval to elect five board nominees (William C. Zachary, George B. Langa, Mark C. Winmill, Russell E. Burke III, and Sally C. Carroll, Esq.) until the 2027 annual meeting, amend and restate the 2017 Equity Incentive Plan, ratify RSM US LLP as independent auditors for FY 2026, and provide advisory approval of executive compensation. The record date is March 30, 2026, with 11,416,754 shares of common stock outstanding. The Board unanimously recommends voting 'FOR' all proposals.

• ·Annual Meeting at 11:00 a.m. ET via live audio webcast only at www.virtualshareholdermeeting.com/SELF2026
• ·Proxy materials mailed on or about April 29, 2026
• ·Company principal executive offices: 3814 Route 44, Millbrook, New York 12545

29-04-2026

Sensata Technologies Holding plc filed its DEF 14A Proxy Statement on April 29, 2026, for the 2026 Annual General Meeting of Shareholders, with voting deadline on June 8, 2026. Key proposals include election of directors, advisory votes on executive and director compensation (including frequency), ratification of independent auditors, approval of amendments to the 2021 Equity Incentive Plan, appointment of UK statutory auditor, receipt of 2025 Annual Report and Accounts, and authorizations for equity issuances and share repurchases. Proxy materials, including the Annual Report on Form 10-K for the year ended December 31, 2025, are available at www.proxyvote.com and investors.sensata.com.

• ·Voting instructions must be received by 11:59 p.m. Eastern Time on June 8, 2026.
• ·Proxy voting available via www.proxyvote.com, telephone (1-800-690-6903), or mail.
• ·Shareholders need 16-digit control number from Notice or proxy card to vote online or by phone.
• ·Registered office: Interface House, Interface Business Park, Bincknoll Lane, Royal Wootton Bassett, Wiltshire, UK SN4 8SY.

29-04-2026

Exzeo Group, Inc. (XZO) has issued its DEF 14A Proxy Statement for the 2026 Annual Meeting on June 9, 2026, seeking shareholder approval for the election of two Class A directors for three-year terms and ratification of Forvis Mazars, LLP as independent auditors for fiscal year 2026. The company highlights significant growth in revenue and earnings in fiscal year 2025, driven by adoption of its Insurance-as-a-Service platform for P&C insurance carriers. The Board of 6 directors, with 4 independent (67%) and 67% contributing to gender or ethnic diversity, held 10 full meetings in 2025 and emphasizes strong governance practices.

• ·Record Date: April 10, 2026
• ·Annual Meeting Location: Exzeo Headquarters, 1000 Century Park Drive, Tampa, Florida 33607, 3:00 p.m. Eastern Time
• ·Auditor served for fiscal year ended December 31, 2025
• ·Dependence on HCI Group, Inc. for substantially all revenues noted in forward-looking statements risks

29-04-2026

HCI Group, Inc. issued its DEF 14A Proxy Statement dated April 29, 2026, for the annual shareholder meeting on June 10, 2026, highlighting record 2025 operating results, return on equity, nearly $1.4B in premiums in force following a policy assumption from Citizens Property Insurance Corp., and the successful IPO of its Exzeo Group, Inc. subsidiary while retaining an 82.5% ownership stake. No declines or flat metrics are mentioned in the provided content. Shareholders will vote on electing one Class B and three Class C directors, ratifying Forvis Mazars, LLP as auditors for 2026, and approving executive compensation on an advisory basis.

• ·Annual meeting: June 10, 2026, 3:00 p.m. ET at 3802 Coconut Palm Drive, Tampa, FL 33619; record date April 13, 2026
• ·Exzeo created in 2012 and taken public via IPO in 2025

29-04-2026

Stifel Financial Corp's DEF 14A proxy statement for the 2026 Annual Meeting discloses executive compensation policies, including deferred compensation grids mandating 0-40% deferrals based on incentive comp levels, risk inputs from CFO and Enterprise Risk Management in pay decisions, at-will employment for executives, double triggers for change-in-control vesting, and anti-hedging/pledging policies. It notes use of independent compensation consultants and 401(k) matches up to $1,000 ($3,000 for lower earners), with no specific named executive pay figures or performance metrics provided in the excerpt.

• ·Deferred comp for non-NEO employees in institutional/admin groups: 5-year ratable annual vesting.
• ·Commission-based deferrals in institutional group: up to 15% on specific products over thresholds.
• ·Double triggers required for accelerated vesting on change-in-control (termination post-CIC needed).
• ·No executive employment agreements; all at-will.
• ·Section 162(m) expansion to more covered employees effective 2027.
• ·Uses non-GAAP measures for PRSU calculations and NEO performance evaluation.

29-04-2026

GoodRx Holdings, Inc. (GDRX) filed its DEF 14A proxy statement on April 29, 2026, for the virtual Annual Meeting of Stockholders on June 16, 2026, seeking approval to elect Wendy Barnes, Ronald E. Bruehlman, and Gregory Mondre as Class III directors until the 2029 annual meeting, ratify KPMG LLP as independent auditors for the fiscal year ending December 31, 2026, and provide advisory approval of named executive officer compensation. The record date is April 20, 2026, with 104,711,186 shares of Class A common stock (4.3% voting power) and 233,964,187 shares of Class B common stock (95.7% voting power) outstanding. No financial performance metrics or period-over-period changes are detailed in the filing.

• ·Annual Meeting to be held virtually via live webcast at www.virtualshareholdermeeting.com/GDRX2026 at 12:00 p.m. Pacific Time.
• ·Stockholders of record as of April 20, 2026 entitled to vote; Class A: 1 vote per share, Class B: 10 votes per share.
• ·Stockholder list available for examination 10 days prior to meeting upon request to legal@goodrx.com.